Day trading pre-market open December 16, page-21

Lots of eyes on ANP this morning waiting for their Phase 2A final results treating DMD

Sarepta Pharpa (US Listed) now worth US10B after popping 35% friday for FDA Approval on its DMD treatment drug. Noting however the FDA has grave concerns about it's safety profile, but approved it anyway "balancing risk / reward" for patients.

If ANP's results this morning show no Safety Concerns it should fly given 30m mkt cap

If, however, ANP can also demonstrate improvement in the disease (i.e. increase in patient strength) then it should go mental IMO

Phase 2A trials have a safety primary endpoint only.